Loading news...
IDEXX Laboratories, Inc. (IDXX) Presents at 47th Annual Raymond James Institutional Investor Conference Prepared Remarks Transcript
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president owned 19,899
IDEXX Laboratories, Inc. (IDXX) Presents at BofA Securities Animal Health Summit Transcript
Lansforsakringar Fondforvaltning AB publ increased its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 3.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,459 shares of the company's stock after buying an additional 963 shares during the quarter. Lansforsakringar Fondforvaltning AB publ's
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Michael Erickson sold 5,371 shares of the business's stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president owned 12,693 shares in the company, valued
Investors looking for stocks in the Medical - Instruments sector might want to consider either SONOVA HOLDING (SONVY) or Idexx Laboratories (IDXX). But which of these two stocks presents investors with the better value opportunity right now?
Idexx's point-of-care platforms, diagnostic tests, and SaaS offerings all help generate recurring revenue. Its leadership as a pick-and-shovel provider to the animal healthcare industry has helped it reap stellar returns.
Factory Mutual Insurance Co. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 25.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,800 shares of the company's stock after selling 15,300 shares during the period. Factory
NEOS Investment Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 82.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,051 shares of the company's stock after buying an additional 13,599 shares during the period. NEOS Investment Management
Fifth Third Bancorp raised its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 23.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,374 shares of the company's stock after acquiring an additional 1,392 shares during the period. Fifth Third
Baron Partners Fund increased 19.07% (Institutional Shares), exceeding its benchmark, the Russell Midcap Growth Index. SpaceX is generating significant value with the rapid expansion of its Starlink broadband service. Shares of global hotelier Hyatt Hotels Corporation increased during the quarter as the company delivered strong revenue per available room and unit growth despite concerns around a weakening macroeconomic environment.
IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) and Vaso (OTCMKTS:VASO - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation. Profitability This table compares IDEXX Laboratories and Vaso's net
Assetmark Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 20.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,251 shares of the company's stock after selling 13,534 shares during the period. Assetmark Inc. owned about 0.06%
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 26, 9:55 am – 10:30 am EST – Mike Lane, Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the virtual BofA Securities Anima.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Candriam S.C.A. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 70.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,975 shares of the company's stock after selling 56,053 shares during the period. Candriam S.C.A.'s holdings in IDEXX Laboratories were
Oppenheimer Asset Management Inc. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 10.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,170 shares of the company's stock after selling 3,458 shares during the period. Oppenheimer
IQ EQ FUND MANAGEMENT IRELAND Ltd decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 59.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,381 shares of the company's stock after selling 1,995 shares during the quarter.
Investors interested in Medical - Instruments stocks are likely familiar with IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
IDEXX Laboratories Inc. (NASDAQ: IDXX) reported better-than-expected fourth-quarter financial results and issued a fiscal 2026 forecast on Monday.